Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2022 | short review

ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer

verfasst von: MSc Dr. Gudrun Piringer

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

In this short review, two late breaking abstracts of neoadjuvant and adjuvant treatment concepts for colorectal cancer presented at ASCO 2022 will be highlighted. Both treatment concepts have the potential to change the standard of care in a subgroup of colorectal cancer patients in the future.
Literatur
1.
Zurück zum Zitat Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40. CrossRefPubMed Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40. CrossRefPubMed
2.
Zurück zum Zitat Bahadoer R, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (Rapido) a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;222:29–42. CrossRef Bahadoer R, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (Rapido) a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;222:29–42. CrossRef
4.
5.
Zurück zum Zitat André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18. CrossRefPubMed André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18. CrossRefPubMed
6.
Zurück zum Zitat Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9. CrossRef Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9. CrossRef
7.
Zurück zum Zitat Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76. CrossRef Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76. CrossRef
8.
Zurück zum Zitat Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7. CrossRefPubMedPubMedCentral Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7. CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346. CrossRef Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346. CrossRef
10.
Zurück zum Zitat Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Eng J Med. 2022;386:2261–72. CrossRef Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Eng J Med. 2022;386:2261–72. CrossRef
Metadaten
Titel
ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer
verfasst von
MSc Dr. Gudrun Piringer
Publikationsdatum
01.11.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00841-6